Fit-For-Purpose PD-L1 Biomarker Testing For Patient Selection in Immuno-Oncology: Guidelines For Clinical Laboratories From the Canadian Association of Pathologists-Association Canadienne Des Pathologistes (CAP-ACP)

Since 2014, programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) checkpoint inhibitors have been approved by various regulatory agencies for the treatment of multiple cancers including melanoma, lung cancer, urothelial carcinoma, renal cell carcinoma, head and neck cancer, c...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Appl Immunohistochem Mol Morphol
Prif Awduron: Cheung, Carol C., Barnes, Penny, Bigras, Gilbert, Boerner, Scott, Butany, Jagdish, Calabrese, Fiorella, Couture, Christian, Deschenes, Jean, El-Zimaity, Hala, Fischer, Gabor, Fiset, Pierre O., Garratt, John, Geldenhuys, Laurette, Gilks, C. Blake, Ilie, Marius, Ionescu, Diana, Lim, Hyun J., Manning, Lisa, Mansoor, Adnan, Riddell, Robert, Ross, Catherine, Roy-Chowdhuri, Sinchita, Spatz, Alan, Swanson, Paul E., Tron, Victor A., Tsao, Ming-Sound, Wang, Hangjun, Xu, Zhaolin, Torlakovic, Emina E.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Lippincott Williams & Wilkins 2019
Pynciau:
Hot Topic
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6887625/
https://ncbi.nlm.nih.gov/pubmed/31584451
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/PAI.0000000000000800
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg